See how Concept Life Sciences accelerated early clinical trials by quickly transferring a client’s process and completing GMP manufacturing of CLS7001.

Small biotechs in early development of cell therapies are often surprised by the strictness of commercial manufacturing standards. That’s the view of Luděk Sojka, PhD, CEO of contract developer and ...

PlasmidFactory GmbH and the Fraunhofer Institute for Cell Therapy and Immunology IZI have signed a Memorandum of Understanding to combine expertise in cell therapy process development and GMP ...

OXB acquires Resilience’s site in North Carolina, an FDA-approved, commercial-scale viral vector manufacturing facility In line with OXB’s ...

Exogenus Therapeutics and Lonza agreed to collaborate on the development of Exo-101, Exogenus’ exosome-based lead candidate. The company specializes in the development of therapeutics based on ...

The launch of the GMP PSXi013 iPSC Master Cell Bank marks a pivotal moment in Pluristyx's ongoing mission to accelerate the development of stem cell therapies. By providing a high-quality, low-passage ...

In today’s fast-paced biopharmaceutical industry, accelerating microbial process development is critical for moving from gene to GMP with greater speed and efficiency. This webinar will highlight ...

BOSTON & SEATTLE & COLUMBUS, Ohio--(BUSINESS WIRE)--GentiBio, Inc., an emerging biotherapeutics company developing best-in-class engineered regulatory T cells programmed to treat autoimmune, ...

OXB has signed and closed an asset purchase transaction to acquire a custom-built cell and gene therapy viral vector manufacturing facility in ...

VANCOUVER, British Columbia, Jan. 21, 2025 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN, FSE: 85W0, OTC PINK: HYTNF) (“HYTN” or the “Company”), a company specializing in pharmaceutical-grade ...